Kiora Pharmaceuticals (KPRX) Competitors $2.53 -0.12 (-4.53%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$2.51 -0.02 (-0.79%) As of 09/19/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPRX vs. MURA, DYAI, XFOR, RANI, MRSN, OKUR, SNTI, RENB, RNTX, and ITRMShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Mural Oncology (MURA), Dyadic International (DYAI), X4 Pharmaceuticals (XFOR), Rani Therapeutics (RANI), Mersana Therapeutics (MRSN), OnKure Therapeutics (OKUR), Senti Biosciences (SNTI), Renovaro (RENB), Rein Therapeutics (RNTX), and Iterum Therapeutics (ITRM). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Its Competitors Mural Oncology Dyadic International X4 Pharmaceuticals Rani Therapeutics Mersana Therapeutics OnKure Therapeutics Senti Biosciences Renovaro Rein Therapeutics Iterum Therapeutics Mural Oncology (NASDAQ:MURA) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment. Does the media favor MURA or KPRX? In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Mural Oncology. MarketBeat recorded 1 mentions for Kiora Pharmaceuticals and 0 mentions for Mural Oncology. Kiora Pharmaceuticals' average media sentiment score of 0.59 beat Mural Oncology's score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Mural Oncology Neutral Kiora Pharmaceuticals Positive Which has more volatility and risk, MURA or KPRX? Mural Oncology has a beta of 2.99, indicating that its share price is 199% more volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.68, indicating that its share price is 168% less volatile than the S&P 500. Do institutionals & insiders believe in MURA or KPRX? 80.2% of Mural Oncology shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 2.2% of Mural Oncology shares are held by company insiders. Comparatively, 0.1% of Kiora Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate MURA or KPRX? Mural Oncology presently has a consensus target price of $12.00, indicating a potential upside of 476.92%. Kiora Pharmaceuticals has a consensus target price of $10.00, indicating a potential upside of 295.26%. Given Mural Oncology's higher possible upside, analysts clearly believe Mural Oncology is more favorable than Kiora Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mural Oncology 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50Kiora Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better valuation & earnings, MURA or KPRX? Kiora Pharmaceuticals has higher revenue and earnings than Mural Oncology. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Mural Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMural OncologyN/AN/A-$128.51M-$8.59-0.24Kiora Pharmaceuticals$16.02M0.54$3.60M-$2.91-0.87 Is MURA or KPRX more profitable? Kiora Pharmaceuticals' return on equity of -47.17% beat Mural Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Mural OncologyN/A -107.76% -87.57% Kiora Pharmaceuticals N/A -47.17%-34.00% SummaryKiora Pharmaceuticals beats Mural Oncology on 7 of the 13 factors compared between the two stocks. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.10M$2.58B$5.79B$10.40BDividend YieldN/A55.37%5.63%4.60%P/E Ratio-0.8722.7276.4826.75Price / Sales0.54689.96531.72124.23Price / Cash2.14175.2537.9261.55Price / Book0.295.3513.726.40Net Income$3.60M$32.95M$3.29B$271.62M7 Day Performance-4.17%0.90%2.66%3.46%1 Month Performance-4.53%5.76%6.02%9.87%1 Year Performance-30.87%-3.43%80.02%28.45% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals2.6521 of 5 stars$2.53-4.5%$10.00+295.3%-32.0%$9.10M$16.02M-0.8710Gap DownMURAMural Oncology2.7368 of 5 stars$2.08+0.2%$12.00+478.3%-39.9%$35.94MN/A-0.24119DYAIDyadic International2.7732 of 5 stars$0.98+1.2%$6.00+514.1%-10.1%$35.50M$3.42M-5.167XFORX4 Pharmaceuticals4.2909 of 5 stars$3.11-8.4%$34.17+1,000.4%-85.1%$35.47M$2.56M-0.2180RANIRani Therapeutics2.5175 of 5 stars$0.49-1.4%$7.33+1,387.5%-77.7%$35.36M$1.03M-0.54110MRSNMersana Therapeutics4.1037 of 5 stars$7.08+0.6%$56.60+699.4%-86.8%$35.28M$40.50M-0.48150OKUROnKure Therapeutics2.7935 of 5 stars$2.59-1.7%$32.33+1,150.8%N/A$34.98MN/A-0.54N/ANews CoverageSNTISenti Biosciences2.5762 of 5 stars$1.33+0.8%$8.50+539.1%-56.9%$34.79M$2.56M-0.154News CoverageShort Interest ↓RENBRenovaro0.4606 of 5 stars$0.20+5.3%N/A-67.4%$33.91MN/A-0.2620Gap UpRNTXRein Therapeutics0.727 of 5 stars$1.38+3.0%N/AN/A$32.17MN/A-0.519ITRMIterum Therapeutics2.7997 of 5 stars$0.68+3.0%$9.00+1,223.5%-38.5%$31.93MN/A-0.8010News CoverageShort Interest ↓Gap Up Related Companies and Tools Related Companies Mural Oncology Competitors Dyadic International Competitors X4 Pharmaceuticals Competitors Rani Therapeutics Competitors Mersana Therapeutics Competitors OnKure Therapeutics Competitors Senti Biosciences Competitors Renovaro Competitors Rein Therapeutics Competitors Iterum Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPRX) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
